Epigenetic therapy supplements docetaxel in the treatment of lung cancer: an in vitro evaluation

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: JAIN, Prateek (Decision Resources Group, Biopharma Insights, Gurgaon, India)
  • Co-author(s): Nayanabhirama Udupa Manipal University, India
    Prateek Jain
  • Abstract:

    Background

    Docetaxel (DTX) is one of the most effective chemotherapeutic agents in the treatment of non-small cell lung cancer. Unfortunately, there is altered response to DTX due to resistance. DNA methylation, an epigenetic event, plays a vital role in cancer and chemotherapy drug resistance. Exploiting the gene reactivation by using

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login